
Quarterly report 2023-Q2
added 08-08-2023
SmileDirectClub Revenue 2011-2026 | SDC
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue SmileDirectClub
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 471 M | 638 M | 657 M | 750 M | 423 M | 146 M | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 750 M | 146 M | 514 M |
Quarterly Revenue SmileDirectClub
| 2023-Q2 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 102 M | - | 107 M | 126 M | 152 M | 126 M | 138 M | 174 M | 199 M | 185 M | 169 M | 107 M | 197 M | 197 M | 180 M | 196 M | 178 M | 129 M | 120 M | 107 M | 68.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 199 M | 68.4 M | 148 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Medical devices industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
AdaptHealth Corp.
AHCO
|
3.24 B | $ 13.14 | 0.23 % | $ 1.78 B | ||
|
BIOLASE
BIOL
|
49.2 M | - | -13.19 % | $ 166 K | ||
|
GenMark Diagnostics, Inc.
GNMK
|
172 M | - | - | $ 1.77 B | ||
|
Allied Healthcare Products
AHPI
|
6.02 M | - | 3.58 % | $ 2.21 M | ||
|
Eargo
EAR
|
37.2 M | - | - | $ 10.2 M | ||
|
Delcath Systems
DCTH
|
85.2 M | $ 10.69 | 2.99 % | $ 383 M | ||
|
Apollo Endosurgery
APEN
|
76.9 M | - | - | $ 475 M | ||
|
Obalon Therapeutics, Inc.
OBLN
|
1.59 M | - | -5.86 % | $ 30.6 M | ||
|
Second Sight Medical Products
EYES
|
1 K | - | -0.97 % | $ 54.4 M | ||
|
Electromed
ELMD
|
64 M | $ 26.13 | 1.04 % | $ 221 M | ||
|
Avinger
AVGR
|
7.65 M | - | -20.74 % | $ 369 K | ||
|
Axonics Modulation Technologies
AXNX
|
274 M | - | - | $ 3.31 B | ||
|
EDAP TMS S.A.
EDAP
|
44.1 M | $ 3.36 | 1.05 % | $ 126 M | ||
|
Aziyo Biologics
AZYO
|
12.3 M | - | 1.37 % | $ 20.5 M | ||
|
BioSig Technologies
BSGM
|
40 K | - | 37.08 % | $ 85.7 M | ||
|
Conformis
CFMS
|
62 M | - | - | $ 16.4 M | ||
|
ClearPoint Neuro
CLPT
|
37 M | $ 11.21 | 0.22 % | $ 317 M | ||
|
Helius Medical Technologies
HSDT
|
644 K | $ 2.09 | 2.21 % | $ 1.27 M | ||
|
Inspire Medical Systems
INSP
|
912 M | $ 56.54 | 0.76 % | $ 1.66 B | ||
|
Cardiovascular Systems
CSII
|
236 M | - | 0.15 % | $ 844 M | ||
|
Cytosorbents Corporation
CTSO
|
37.1 M | $ 0.63 | 2.87 % | $ 39.2 M | ||
|
CryoLife, Inc.
CRY
|
253 M | - | -4.14 % | $ 702 M | ||
|
Invacare Corporation
IVC
|
181 M | - | - | $ 24.7 M | ||
|
LivaNova PLC
LIVN
|
1.39 B | $ 60.35 | 0.42 % | $ 3.29 B | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
4.25 K | - | -1.98 % | $ 98.3 M | ||
|
IRIDEX Corporation
IRIX
|
52.7 M | $ 1.08 | 4.37 % | $ 18.3 M | ||
|
Itamar Medical Ltd.
ITMR
|
41 M | - | 0.03 % | $ 1.58 B | ||
|
Dynatronics Corporation
DYNT
|
27.4 M | - | 14.99 % | $ 929 K | ||
|
Misonix, Inc.
MSON
|
62.5 M | - | - | $ 462 M | ||
|
Neovasc
NVCN
|
2.55 M | - | - | $ 111 M | ||
|
OrthoPediatrics Corp.
KIDS
|
236 M | $ 15.26 | 1.29 % | $ 358 M | ||
|
Butterfly Network
BFLY
|
82.1 M | $ 4.9 | 2.51 % | $ 1.04 B | ||
|
Intersect ENT, Inc.
XENT
|
80.6 M | - | - | $ 955 M | ||
|
GBS
GBS
|
3.05 M | - | -0.57 % | $ 7.12 M | ||
|
Globus Medical
GMED
|
2.94 B | $ 90.84 | 0.7 % | $ 12.3 B | ||
|
NanoVibronix
NAOV
|
2.55 M | - | - | $ 1.08 M | ||
|
CONMED Corporation
CNMD
|
1.37 B | $ 37.36 | 1.77 % | $ 1.16 B | ||
|
Integer Holdings Corporation
ITGR
|
1.85 B | $ 87.13 | -1.61 % | $ 3.03 B | ||
|
Edwards Lifesciences Corporation
EW
|
6.07 B | $ 83.61 | 0.1 % | $ 48.9 B | ||
|
Sintx Technologies
SINT
|
1.02 M | $ 2.08 | 0.2 % | $ 5.77 M | ||
|
Stryker Corporation
SYK
|
7.17 B | $ 304.09 | -3.48 % | $ 116 B | ||
|
TransMedics Group
TMDX
|
605 M | $ 100.78 | -0.01 % | $ 3.43 B | ||
|
LENSAR
LNSR
|
58.4 M | $ 5.21 | -0.38 % | $ 62.3 M | ||
|
Tandem Diabetes Care
TNDM
|
290 M | $ 19.81 | 1.46 % | $ 1.35 B | ||
|
Pulmonx Corporation
LUNG
|
90.5 M | $ 1.33 | 3.91 % | $ 54.1 M | ||
|
MiMedx Group
MDXG
|
419 M | $ 3.58 | 6.55 % | $ 529 M | ||
|
Myomo
MYO
|
40.9 M | $ 0.87 | 1.21 % | $ 36.4 M |